The DECISION project held its 6th General Assembly from October 16–18, 2024, in Bologna, Italy, focusing on novel therapies, biomarker validation, and clinical translation for acutely decompensated cirrhosis.

Scientific Highlights:

• Epigenetics and Transcriptomics: Estefania Huergo presented on epigenetic signatures, while Richard Moreau highlighted RNA-sequencing data, both offering insights into predicting adverse outcomes and mortality risks.
• Biomarker Discovery: Johanna Reissing and Cristina López-Vicario identified potential biomarkers like microRNAs and inflammatory proteins linked to disease progression and ACLF risk. Pierre-Emmanuel Rautou discussed extracellular vesicles and their correlation with mortality.
• Preclinical Models: Frank Uschner showcased progress in preclinical models testing combinatorial therapies like albumin and enoxaparin for ACLF.
• Patient Stratification: David Gomez-Cabrero reported advancements in predicting outcomes using multi-omics data.
• Clinical Trials: Paolo Caraceni outlined the COMBAT trial, assessing a combinatorial therapy, and the PROSPECT study focusing on biomarker validation and survival prediction.

Outreach and Impact: Tamara Berghammer emphasized dissemination efforts through a dedicated website, social media, and conference participation, ensuring the project’s influence and visibility.

The assembly concluded with a summary of progress in identifying new therapeutic strategies for liver disease, underscoring the consortium’s dedication to translating research into clinical practice.

Article is adapted from the EF-CLIF's news piece here.